Follow us
CBD GMP Health

Good Clinical Practice (GCP) For Medical Cannabis

Written by Eran Yona

Good Clinical Practices (GCPs) are international ethical and scientific quality standards for the design, conduct, performance, monitoring, auditing, analysis, reporting and regulation of human clinical investigations…

Clinical investigations are experiments and studies in which a medical product such as a drug or device is administered or dispensed to, or used involving, one or more human subjects. Documentation of compliance with GCP standards is required for clinical investigations submissions to the regulatory ‎agencies in USA, Europe, Japan and Canada. These standards provide assurance that the rights and confidentiality of the trial subjects are protected and that the data and reported results are credible and accurate.

Compliance with clinical investigations registration standards provide public assurance that the rights, safety, and wellness of human subjects are followed and protected.

ICH (Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use) GCP guidance objective is to provide a unified mutual standard for United States, the European Union (EU) and Japan for clinical data by the regulatory authorities in these jurisdictions.

The guidance was developed considering the current best clinical practices of the United States, European Union, Japan, Australia, Canada, the Nordic countries, and the World Health Organization (WHO). ICH “efficacy” have many topics (E1 to E12A). ICH – E6 is relevant to Good Clinical Practice.

If you want to read the full original article, and get some more in-depth details regarding best practices for the cannabis industry, please click here.

[Image credit- Pixabay]

Have anything to add? Your voice matters! Join the conversation and contribute your insights and ideas below.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

About the author

Eran Yona

Eran Yona has more than 20 years experience in the field of Biotechnology, most notably in the Medical and Pharmaceutical industries.

Prior to founding Cannabis GxP and Bio-Chem in 2007, Eran worked in R&D in the field of genetically modified plant tissue culture, as well as a product development & technology Engineer, and Production & Operations Manager in several pharmaceutical and Agri-Bio companies.

Six years ago, following Bio-Chem’s great success in consultancy and services for the Pharma and Medical industries, Eran decided to extend and expand Bio-Chem’s capabilities to the young but promising Cannabis industry.

Eran and his dedicated team have lead many Cannabis companies to regulatory, technological, and financial success.